Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Malachite Innovations Inc., MLCT, changed to Range Impact Inc, RNGE:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
Things are looking up.
https://malachiteinnovations.com/2022-annual-report-highlights/
They jettisoned Robert in May of 2019!
Starting to look a lot like STVF. Someone is making a bunch of money based on some poor suckers mistakes. Right Robert ? Now that's what I call "EASY PEASY"
Someone is still buying Malachite in volume every few days. 41,906 shares at 15:30 yesterday.
It looks like most individual shareholders have written off Malachite, and based on the company's performance it's not hard to see why!
Good volume on MLCT today out of the blue.
"We also expect to obtain additional financing and other sources of capital to fund our planned future operations."
https://www.sec.gov/ix?doc=/Archives/edgar/data/1438943/000149315222012627/form10-q.htm
MALACHITE INNOVATIONS ANNOUNCES SIGNED LETTER OF
INTENT WITH RANGE ENVIRONMENTAL RESOURCES, INC.
https://www.sec.gov/Archives/edgar/data/0001438943/000149315222006892/ex99-1.htm
single transaction 53,000 shares purchased at 14 cents
Oh snap! Even selling at 16 cents!
Oh snap! Even selling at 16 cents!
Not much selling going on with the bid price at 16.6 cents.
At the end of the day, the bid was 12.5 cents and the ask was 21.5 cents.
It will be interesting to see if anyone unloads at that level. I can't figure out why this company went to all the effort of a makeover?
Absolute silence from mlct. It looks like a market maker dropped the ask and bid. For weeks now, the ask was held around 30 cents, even though hardly anyone was buying, mostly selling.
I haven't heard anything. Volume today is almost 10x normal, and MLCT is down 20% on the day.
I snagged some more shares at .181 and at .18
Anybody heard anything positive about MLCT's prospects lately? I seem to be monopolizing this forum.
MALACHITE INNOVATIONS ANNOUNCES TWO GRANTED
U.S. PATENTS AND NEW PCT PATENT FILING
https://www.sec.gov/Archives/edgar/data/0001438943/000149315221032599/ex99-1.htm
Insider Transactions 12-10 https://www.sec.gov/edgar/browse/?CIK=0001438943
A Market Maker seems to be acquiring thousands of MLCT shares around 30-35 cents, with hardly any buyer interest in those shares in the upper thirties.
There appears to be a market maker accumulating MLCT at $.35, and keeping the bid there, to accumulate even more.
Legit management now.
A team, a plan, and money to last into the start of 2023. This is finally getting started!
Sure hope that Cavanaugh has a next move.
We will hope for the best.
Consider it like a hard reset of a computer. All the same power and back-end, but you get a chance to rename it and remove the junk ware
Pretty much a mess! Confusion about the new symbol, and really no value added to this company, especially with almost no funds on hand.
Effective Oct. 12,2021 Vitality Biopharma Inc., VBIO, will change to Malachite Innovations Inc., MLCT:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
The 2 symbols are pretty different?
Correction... $VBHI Verde Bio Holdings CEO Live on the Emerging Growth Conference on October 13, 2021
Originally we accidentally posted $VBIO would be presenting.
Register here to interact Live:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166295083
Who else would you like to see?
email:
Conference@EmergingGrowth.com
or
Call the number here:
http://EmergingGrowth.com/Conference
Might be fun to ask Cavanaugh about what the heck is going on at VBIO.
They should be out of cash at this point.
$VBIO Vitality Biopharma CEO Live on the Emerging Growth Conference on October 13, 2021
Register here to interact Live - Link on the EGC page.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166283787
Who else would you like to see?
email:
Conference@EmergingGrowth.com
or
Call the number here:
http://EmergingGrowth.com/Conference
It's under 14m market cap. Hell yeah its a buying opportunity
I hope it continues the climb!
24,000 SHARE BUY ON WAY BACK UP @ 77 CENTS $$$$$$$$$$$$$$$$$$$$$$
Followers
|
58
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2432
|
Created
|
03/05/12
|
Type
|
Free
|
Moderators |
Vitality Biopharma (“Vitality”) (OTCQB: VBIO) is a cure development company, dedicated to unlocking the power of cannabinoid “prodrugs” as a means to treat serious neurological and inflammatory disorders. We are interested in drug approvals first and foremost, but our overarching mission is to improve the lives of patients afflicted with devastating neurological and inflammatory conditions, such as multiple sclerosis. We aim to go beyond providing symptomatic relief to patients afflicted with these disorders, such as treatment of muscle spasticity in multiple sclerosis, and to instead identify combination treatments that treat the underlying cause of disease and hold the potential to help patients recover lost function.
Prodrugs are medications or compounds that, after administration, are converted within the body into a pharmacologically active drug, which may already have a long history of clinical investigation and use. Because the reference drug already has independent verification of its safety and efficacy, the prodrug may be approved rapidly through demonstrating similar bioavailability or bioequivalence, and at the same time a prodrug can be far more marketable due to its ability to eliminate unwanted side effects or undesirable commercial aspects. A classic prodrug example is Aspirin, acetylsalicylic acid, which was first made by Felix Hoffmann at Bayer in 1897 and is a synthetic prodrug of salicylic acid. As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.
One of the most hotly pursued cannabinoids for pharmaceutical purposes is cannabidiol, which is non-psychotropic, and has demonstrated therapeutic effects in clinical trials for serious neurological conditions including rare seizure disorders and for alleviating symptoms of multiple sclerosis. Our prodrugs could exert the same beneficial therapeutic effects, but with notable improvements, such as a better tasting formulation that enables improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, or a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief. Given that we have recently filed intellectual property applications including strong composition of matter claims for more than 30 cannabinoid prodrugs, including versions of THC, CBD, and CBDV, we have demonstrated the ability to create a proprietary prodrug of every significant cannabinoid pharmaceutical available today.
Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.
Independent clinical trial results suggest that cannabinoids will help induce remission in Crohn’s disease patients, and that the vast majority of inflammatory bowel disease patients experience symptomatic relief, including more than 75% of patients who report improvement in visceral pain and abdominal cramping. Approximately 1.4 million Americans are affected by inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. Most patients are diagnosed before age 30 and require life-long treatment.
In addition to providing targeted delivery, cannabosides could enable a better tasting formulation for improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, and a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief.A prodrug is a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Prodrugs are often designed to improve bioavailability when a drug itself is poorly absorbed from the gastrointestinal tract, or to overcome other issues that make molecules unappealing candidates for future development efforts. A prodrug may for instance be used to selectively target a specific tissue or organ, such as the brain or gut, which enables the drug to have a more targeted effect. Prodrugs have been around for a while, with Aspirin, acetylsalicylic acid, first made by Felix Hoffmann at Bayer in 1897, a classic example of a synthetic prodrug of salicylic acid. As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.
Our compounds take advantage of a targeted-release mechanism where microbial enzymes present in the intestines will enable a very site-specific localized release of compounds including THC, CBD, and many of the other known cannabinoids. Because of this, we could provide targeted relief of inflammatory bowel diseases (IBD) such as Crohn’s disease or ulcerative colitis, simply by enabling larger doses of cannabinoids to be delivered.
click photo to view presentation
Through extensive research in the natural sweetener industry, we pioneered industrial-scale processes to modify stevia to make it taste better. This process is known as glycosylation, which involves adding additional glucose molecules to it, and it modifies both the taste and solubility of it. Over the last 10 years or so, it has become appreciated within the pharmaceutical industry that glycosylation could act to generate new natural product libraries with improved drug properties. This process for modifying natural products to make them more useful is often called glycorandomization, or glycodiversification.
Using the same technology, we’ve now been able to produce and characterize more than 20 novel cannabinoid glycosides, or “cannabosides”, which are novel cannabinoid prodrug pharmaceuticals. As an example, one of the most hotly pursued cannabinoids for pharmaceutical purposes is cannabidiol, which is non-psychotropic, and has potential therapeutic effects in a wide variety of serious neurological and inflammatory conditions. Our prodrugs could exert the same beneficial therapeutic effects, but with notable improvements, such as site-specific delivery that avoids or reduces psychoactivity, a better tasting formulation for improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, and a delayed release mechanism that could enable long-lasting, overnight relief.
Vitality has filed intellectual property applications including strong composition of matter claims for prodrugs of THC, CBD, and CBDV, creating proprietary prodrugs of every significant cannabinoid pharmaceutical available today.
Vitality Biopharma, Inc.
1901 Avenue of the Stars
2nd Floor
Los Angeles, California
90067
Telephone: (530) 231-7800
Fax: (866) 293-0655
Email: info@vitality.bio
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |